[go: up one dir, main page]

WO2008103905A3 - Anticorps qui se lient spécifiquement à irta et son procédé d'utilisation - Google Patents

Anticorps qui se lient spécifiquement à irta et son procédé d'utilisation Download PDF

Info

Publication number
WO2008103905A3
WO2008103905A3 PCT/US2008/054720 US2008054720W WO2008103905A3 WO 2008103905 A3 WO2008103905 A3 WO 2008103905A3 US 2008054720 W US2008054720 W US 2008054720W WO 2008103905 A3 WO2008103905 A3 WO 2008103905A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
specifically bind
methods
irta5
irt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/054720
Other languages
English (en)
Other versions
WO2008103905A2 (fr
Inventor
Ira Pastan
Satoshi Nagata
Tomoko Ise
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of WO2008103905A2 publication Critical patent/WO2008103905A2/fr
Publication of WO2008103905A3 publication Critical patent/WO2008103905A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Rehabilitation Therapy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des anticorps qui se lient spécifiquement au domaine extracellulaire de IRT A3 ou au domaine extracellulaire de IRTA5. Les anticorps qui se lient spécifiquement à IRT A3 ne se lient pas spécifiquement à IRTAl, IRT A2, IRTA4, IRTA5 ou IRTA6. Les anticorps qui se lient spécifiquement à IRTA5 ne se lient pas spécifiquement à IRTAl, IRTA2, IRTA3, IRTA4, ou IRTA6. Les anticorps peuvent être conjugués avec des molécules effectrices, notamment des étiquettes détectables, des radionucléotides, des toxines et des agents chimiothérapeutiques. L'invention concerne également des molécules d'acides nucléiques codant pour ces anticorps, des vecteurs d'expression, des cellules hôtes, et des méthodes pour exprimer des anticorps. L'invention concerne en outre les méthodes pour détecter IRTA5 ou IRT A3, ainsi que des méthodes pour traiter des malignités diverses de lymphocytes B. L'invention concerne enfin des méthodes pour évaluer l'efficacité d'une thérapie sur une maladie auto-immune.
PCT/US2008/054720 2007-02-23 2008-02-22 Anticorps qui se lient spécifiquement à irta et son procédé d'utilisation Ceased WO2008103905A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89143407P 2007-02-23 2007-02-23
US60/891,434 2007-02-23

Publications (2)

Publication Number Publication Date
WO2008103905A2 WO2008103905A2 (fr) 2008-08-28
WO2008103905A3 true WO2008103905A3 (fr) 2008-12-31

Family

ID=39561949

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/054720 Ceased WO2008103905A2 (fr) 2007-02-23 2008-02-22 Anticorps qui se lient spécifiquement à irta et son procédé d'utilisation

Country Status (1)

Country Link
WO (1) WO2008103905A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10196458B2 (en) * 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof
US10578619B2 (en) 2013-07-31 2020-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for identifying effector Treg cells
SG10202100324YA (en) 2017-04-10 2021-02-25 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
US10899819B2 (en) 2017-04-10 2021-01-26 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
BR112020016374A2 (pt) * 2018-02-13 2020-12-15 Precision Biologics, Inc. Métodos e composições para direcionar células treg
GB201820157D0 (en) * 2018-12-11 2019-01-23 Imperial Innovations Ltd Method of treatment
CN115197320A (zh) * 2021-04-07 2022-10-18 中美冠科生物技术（太仓）有限公司 新型抗cd4抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089624A2 (fr) * 2002-03-25 2003-10-30 Uab Research Foundation Elements de la famille des genes homologues des recepteurs de fc (fcrh1-3, 6), reactifs associes et utilisations de ces derniers
WO2006039238A2 (fr) * 2004-09-30 2006-04-13 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anticorps de irta2 et méthodes d'utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089624A2 (fr) * 2002-03-25 2003-10-30 Uab Research Foundation Elements de la famille des genes homologues des recepteurs de fc (fcrh1-3, 6), reactifs associes et utilisations de ces derniers
WO2006039238A2 (fr) * 2004-09-30 2006-04-13 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anticorps de irta2 et méthodes d'utilisation

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DAVIS R S ET AL: "Fc receptor homologs: Newest members of a remarkably diverse Fc receptor gene family", IMMUNOLOGICAL REVIEWS, MUNKSGAARD, XX, vol. 190, 1 January 2002 (2002-01-01), pages 123 - 136, XP002971663, ISSN: 0105-2896 *
DAVIS R S ET AL: "Identification of a family of Fc receptor homologs with preferential B cell expression", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, vol. 98, no. 17, 14 August 2001 (2001-08-14), pages 9772 - 9777, XP002971662, ISSN: 0027-8424 *
DAVIS RANDALL S ET AL: "An extended family of Fc receptor relatives.", EUROPEAN JOURNAL OF IMMUNOLOGY MAR 2005, vol. 35, no. 3, March 2005 (2005-03-01), pages 674 - 680, XP002487227, ISSN: 0014-2980 *
DAVIS RANDALL S ET AL: "Differential B cell expression of mouse Fc receptor homologs.", INTERNATIONAL IMMUNOLOGY SEP 2004, vol. 16, no. 9, September 2004 (2004-09-01), pages 1343 - 1353, XP002487225, ISSN: 0953-8178 *
DAVIS RANDALL S: "Fc receptor-like molecules.", ANNUAL REVIEW OF IMMUNOLOGY 2007, vol. 25, 2007, pages 525 - 560, XP002487228, ISSN: 0732-0582 *
LEU CHUEN-MIIN ET AL: "FcRH1: an activation coreceptor on human B cells.", BLOOD 1 FEB 2005, vol. 105, no. 3, 1 February 2005 (2005-02-01), pages 1121 - 1126, XP002487229, ISSN: 0006-4971 *
MILLER IRA ET AL: "IRTAs: A new family of immunoglobulinlike receptors differentially expressed in B cells", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, vol. 99, no. 8, 15 April 2002 (2002-04-15), pages 2662 - 2669, XP002351572, ISSN: 0006-4971 *
POLSON ANDREW G ET AL: "Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia.", INTERNATIONAL IMMUNOLOGY SEP 2006, vol. 18, no. 9, September 2006 (2006-09-01), pages 1363 - 1373, XP002487226, ISSN: 0953-8178 *
WON WOONG-JAI ET AL: "Fc receptor homolog 3 is a novel immunoregulatory marker of marginal zone and B1 B cells.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 NOV 2006, vol. 177, no. 10, 15 November 2006 (2006-11-15), pages 6815 - 6823, XP002487224, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
WO2008103905A2 (fr) 2008-08-28

Similar Documents

Publication Publication Date Title
WO2008103905A3 (fr) Anticorps qui se lient spécifiquement à irta et son procédé d'utilisation
WO2006039238A3 (fr) Anticorps de irta2 et méthodes d'utilisation
DE602004018141D1 (de) Polypeptide mit bindungsaffinität für her2
WO2007002223A3 (fr) Anticorps cd19 et utilisations
WO2008112274A3 (fr) Mutations de k-ras et de b-raf et thérapie utilisant des anticorps anti-egfr
WO2008050255A3 (fr) Agents de contraste destinés à détecter un cancer de la prostate
WO2008045976A3 (fr) Compositions et méthodes pour le traitement et le diagnostic de cancers
EP2318088A4 (fr) Ensembles et systèmes portatifs permettant d'apporter une neurostimulation fonctionnelle ou thérapeutique et procédés associés
WO2006124641A3 (fr) Anticorps diriges contre la mesotheline utiles pour des dosages immunologiques
WO2006076691A3 (fr) Anticorps 2 associes a la translocation de recepteur immunitaire (irta-2) et leurs utilisations
WO2008136848A3 (fr) Nouveaux anticorps anti-notch3 et leur utilisation dans la détection et le diagnostic d'une maladie
WO2005097185A3 (fr) Anticorps irta-5 et utilisations de ces derniers
WO2009073533A3 (fr) Conjugués anticorps monoclonal-médicaments anti-b7h4 et procédés d'utilisation associés
WO2008074004A3 (fr) Anticorps humains se liant à cd70 et utilisations de ceux-ci
WO2006002161A3 (fr) Modulateurs de recepteurs odorants
WO2010078950A3 (fr) Antigènes associés à l'endométriose, au rhumatisme psoriasique et au psoriasis
WO2008012362A3 (fr) Nouvelles protéines isoformes et leur utilisation
Zaidi et al. Binding mode characterization of 6α-and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: Application of the ‘message–address’ concept in development of mu opioid receptor selective antagonists
ATE504602T1 (de) Für humane matriptase spezifische bindungsproteine
WO2007112054A3 (fr) Facilitation de la translocation de molecules a travers le tractus gastro-intestinal
WO2005070456A8 (fr) Diagnostic et traitement du cancer
WO2007087263A3 (fr) Citrate, zinc et zip1 humain destines au criblage d’un cancer de la prostate
SE0301987D0 (sv) New polypeptide
Martens Role of C2 domain proteins during synaptic vesicle exocytosis
EP2238981A4 (fr) Composition de polysaccharides mucilagineux dérivés d'aloe barbadensis, en combinaison avec des liposomes, et procédé d'obtention et d'utilisation de cette composition comme photoprotecteur, agent anti-acné, régénérateur de l'épiderme et hydratant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08730511

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08730511

Country of ref document: EP

Kind code of ref document: A2